

# REXIS BIOTECH ANNOUNCES THE OFFICAL APPROVAL AND LAUNCH OF IT'S FUSED POLYMPORPH NANO FIBER TECHNOLOGY

*Rexis Biotech launches its proprietary drug delivery platform, Fused Polymorph Nano Fiber.*

LAS VEGAS, NV, UNITED STATES, March 17, 2023 /EINPresswire.com/ -- Rexis Biotech Inc. ("REXIS") is delighted to announce that, after more than three years of development and clinical trials, its innovative co-crystal formation and drug delivery platform, Fused Polymorph Nano Fiber TM, has received approval for use and distribution in the United States.



Fused Polymorph Nano Fiber TM is a pioneering co-crystal fusing technology that transforms hydrophobic molecules, such as THC and CBD, into hydrophilic, water-soluble molecules. This breakthrough has broad applications across various industries, including prodrug pharmaceutical medications, consumer packaged goods, and research projects.

In the following weeks, Rexis will announce several profitable licensing agreements with both domestic and international corporations that have licensed Fused Polymorph Nano Fiber TM. These early adopters of the technology have collaborated closely with the Rexis development team to create several ground-breaking product advancements with the potential to revolutionize the pharmaceutical and consumer packaged goods industries.

Keith Bushfield, Rexis CEO, stated, "We are thrilled to announce the approval of our novel drug delivery platform, Fused Polymorph Nano Fiber TM, for use in the United States. We are also delighted with the overwhelming demand and acceptance of our technology, not only within the scientific community but also among product developers worldwide."

On Behalf of the Board of Directors of

Rexis Biotech Inc.  
Keith Bushfield  
CEO/President

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

#### About Rexis Biotech Inc.

Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams. For more information, please visit: [www.rexisystems.com](http://www.rexisystems.com)

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

Ryan Erving  
REXIS BIOTECH - Information Request  
+1 415-314-7133  
[Ryan@rexissystems.com](mailto:Ryan@rexissystems.com)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/622780630>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.